Gleiss Lutz advises Roche on the sale of Roche Diagnostics IT Solutions GmbH to Nexus AG
Gleiss Lutz advised Roche on the sale of Roche Diagnostics IT Solutions GmbH to the healthcare software provider Nexus AG (Nexus). In the course of the transaction, Nexus will acquire the laboratory products “Swisslab Laboratory Information System” and “Lauris Order Communication System”, which are among the leading laboratory information systems in Europe. The closing of the transaction is scheduled to take place on 30 November 2018.
Currently, over 300 Swisslab installations generate more than 350,000 laboratory results in Germany. The company’s customers include not only several German university clinics, but also a growing number of hospitals, laboratory networks, diagnostic centres and medical specialist laboratories. The Roche Group, headquartered in Basel, Switzerland, operates as a research-based company in more than 100 countries with over 94,000 employees worldwide in the fields of pharmaceuticals, diagnostics and diabetes management.
Nexus is one of Europe’s leading software providers in the healthcare sector. With over 1,100 employees, the Donaueschingen-based company provides modern IT applications to hospitals, rehab facilities and retirement homes in 21 European countries and the Middle East. The stock corporation, which is traded in the Prime Standard segment of the Frankfurt Stock Exchange, generated turnover of around EUR 119 million in the 2017 financial year.
Dr. Tatjana Linder und Dr. Valentin Baltzer from Roche’s legal department acted as lead counsel on the transaction.
Roche was advised on the transaction by a Gleiss Lutz team which was led by Dr. Alexander Schwarz (partner, Corporate/M&A, Düsseldorf) and Dr. Martin Viciano Gofferje (partner, Corporate/M&A, Berlin) and consisted of the following lawyers: Vanessa Sánchez López (Corporate/M&A, Berlin), Julian Jantze (Corporate/M&A, Düsseldorf), Dr. Achim Dannecker (partner), Dr. Hanna Datzer (both Tax, Stuttgart), Dr. Rut Steinhauser (Employment, Berlin), Dr. Alexander Molle (counsel), Dr. Matthias Schilde (both Intellectual Property, Berlin), Dr. Marco König (partner), Dr. Oliver Jürgen Junge (both Public Law, Stuttgart).
Gleiss Lutz has a leading practice in the healthcare sector, in which it combines the industry-specific know-how and the expertise of specialists from a wide range of relevant legal fields. The law firm advises regularly on complex and high-volume national and international transactions, most recently, for example, the German pharmaceuticals group Boehringer Ingelheim on the acquisition of ViraTherapeutics, as well as the private equity investor Porterhouse on its takeover of the insolvent Paracelsus clinic group.